Author

Xuan Ying Poh

Observed names: Poh, Xuan Ying, X.Y. Poh

Institutions: National Centre for Infectious Diseases, Communicable Diseases Agency

Observed institutions: National University of Singapore, Hammersmith Hospital, Tan Tock Seng Hospital, National Centre for Infectious Diseases, Communicable Diseases Agency, Imperial College London

ORCID: 0000-0001-6077-0515

Observed ORCID: 0000-0001-6077-0515

OpenAlex ID: A5091511364

Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial

2022 · Xuan Ying Poh, Chee Wah Tan, et al. · Clinical Infectious Diseases · 50

PDF

Neutrophil-Mediated Immunopathology and Matrix Metalloproteinases in Central Nervous System – Tuberculosis

2022 · Xuan Ying Poh, Fei Kean Loh, et al. · Frontiers in Immunology · 36

PDF

Selective transduction of astrocytic and neuronal CNS subpopulations by lentiviral vectors pseudotyped with Chikungunya virus envelope

2017 · Ioanna Eleftheriadou, Michael Dieringer, et al. · Biomaterials · 21

Nos2−/− mice infected with M. tuberculosis develop neurobehavioral changes and immunopathology mimicking human central nervous system tuberculosis

2022 · Xuan Ying Poh, Jia Mei Hong, et al. · Journal of Neuroinflammation · 11

PDF

MMPs and NETs are detrimental in CNS-tuberculosis with MMP Inhibition in CNS-tuberculosis mice improving survival

2025 · Xuan Ying Poh, Fei Kean Loh, et al. · Journal of Neuroinflammation · 10

PDF

First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial

2024 · Xuan Ying Poh, I. Russel Lee, et al. · EBioMedicine · 7

Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

2022 · Xuan Ying Poh, I. Russel Lee, et al. · Trials · 6

PDF

Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial

2026 · Sheena G Sullivan, Xuan Ying Poh, et al. · The Lancet Infectious Diseases · 5

PDF

Modeling Antibody Kinetics Post‐mRNA Booster Vaccination and Protection Durations Against SARS‐CoV‐2 Infection

2025 · Luis J. Ponce, Yuqian Wang, et al. · Journal of Medical Virology · 5

Efficient recall of SARS‐CoV‐2 variant‐reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters

2022 · Angeline Rouers, Nathan Wong, et al. · Journal of Medical Virology · 5

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant

2023 · Matthew Zirui Tay, Yun Shan Goh, et al. · The Lancet Regional Health - Western Pacific · 4

Variant-Specific IgA Protects Against Omicron Infection

2023 · Yun Shan Goh, Siew-Wai Fong, et al. · The Journal of Infectious Diseases · 3

PDF

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

2024 · Xuan Ying Poh, Anthony Torres-Ruesta, et al. · Vaccine · 2

Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1)

2024 · Yun Shan Goh, Siew‐Wai Fong, et al. · International Journal of Infectious Diseases · 1

PDF

Central Nervous System Tuberculosis Immunopathology Is Driven by Matrix Destruction With Matrix Metalloproteinases Inhibition Reducing Inflammation and Improving Survival

2023 · X.Y. Poh, F.K. Loh, et al. · International Journal of Infectious Diseases · 1

PDF

NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

2026 · Poh, Xuan Ying, Mah, Shirley Y. Y., et al. · Figshare

NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants

2026 · Xuan Ying Poh, Shirley Y. Y. Mah, et al. · Human Vaccines & Immunotherapeutics

Preliminary results from the first human challenge study in Singapore -a Delta SARS-CoV-2 controlled human infection model (CHIM) in seropositive adults

2026 · Poh, Xuan Ying, Chan, Conrad, et al.

Antibody kinetics following mRNA booster vaccination as correlates of protection against SARS-CoV-2 infection

2025 · Luis Ponce, Yuqian Wang, et al. · IJID Regions

Randomised Immunogenicity Trial Comparing 2022/2023 Season Recombinant, Cell-Based, and Egg-Based Influenza Vaccines Among Infrequently and Frequently Vaccinated Healthy Younger Adults

2025 · Sheena G. Sullivan, Xuan Ying Poh, et al. · SSRN Electronic Journal

Platelets aggregate in tuberculomas and augment NETs and MMP to worsen TB immunopathology in clinical, murine and in vitro studies

2024 · Hyeyoung Lee, Fei Kean Loh, et al. · European Respiratory Journal

Immunopathology of Diabetes Mellitus in Pulmonary Tuberculosis Is Driven by Neutrophil Hyper-inflammatory Dysfunction: Data From a Cellular Model and Human Cohort.

2023 · P.M. Thong, C. Bai, et al. · International Journal of Infectious Diseases

Correction to: Nos2−/− mice infected with M. tuberculosis develop neurobehavioral changes and immunopathology mimicking human central nervous system tuberculosis

2022 · Xuan Ying Poh, Jia Mei Hong, et al. · Journal of Neuroinflammation

PDF

Nos2 -/- Mice Infected With M. Tuberculosis Develop Neurobehavioral Changes and Immunopathology Mimicking Human Central Nervous System Tuberculosis

2021 · Xuan Ying Poh, Jia Mei Hong, et al. · Research Square

PDF

Works count: 35

Citation count: 167

H-index: 6

I10-index: 5